The economic reality of Alzheimer's treatment reveals a troubling disparity that could reshape how families and healthcare systems approach early dementia care. While older medications demonstrate clear value, newer breakthrough therapies struggle to justify their astronomical costs under standard health economic frameworks.
A comprehensive analysis of 23 cost-effectiveness studies found that traditional cholinesterase inhibitors—memantine, donepezil, rivastigmine, and galantamine—consistently meet accepted value thresholds of $100,000 per quality-adjusted life year. In contrast, the recently approved monoclonal antibodies aducanumab, lecanemab, and donanemab failed to achieve cost-effectiveness at this standard benchmark across all evaluated studies. The systematic review employed rigorous Markov modeling approaches and examined perspectives from both healthcare systems and broader society.
This economic divide reflects a fundamental challenge in neurotherapeutic development. The older medications, despite modest symptomatic benefits, offer demonstrable value through their low acquisition costs and established safety profiles. Meanwhile, the newer antibody treatments—designed to target amyloid plaques directly—carry price tags that appear disconnected from their clinical impact. The analysis suggests value-based pricing for the novel agents would need to drop below $5,000 annually to achieve cost-effectiveness at $150,000 per quality-adjusted life year thresholds. This represents a dramatic reduction from current market pricing, highlighting the tension between innovation incentives and healthcare affordability. For patients and families navigating treatment decisions, these findings underscore the importance of considering both clinical outcomes and long-term financial sustainability when evaluating therapeutic options.